Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dyslipidemia in patients with chronic and end-stage kidney disease.

Literature DB >> 24454313

Dyslipidemia in patients with chronic and end-stage kidney disease.

Jad Omran, Ashraf Al-Dadah, Kevin C Dellsperger.

Abstract

In this review, we discuss the physiology, diagnosis and treatment of dyslipidemia in patients with chronic and end-stage renal disease. The recent important clinical trials in patients with chronic kidney disease and dyslipidemia are reviewed. Because of the lack of evidence in treating lipid abnormalities in this specific patient population, we propose that future studies should focus on the pathophysiological mechanisms and treatment of dyslipidemia in this special patient population.

Entities: Chemical Disease Species

Keywords: Chronic kidney disease; Dyslipidemia; End-stage renal disease; Oxidized low-density lipoprotein

Year: 2013 PMID： 24454313 PMCID： PMC3884190 DOI： 10.1159/000351985

Source DB: PubMed Journal: Cardiorenal Med ISSN： 1664-5502 Impact factor: 2.041

97 in total

1. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors: P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal: N Engl J Med Date: 2001-06-28 Impact factor: 91.245

2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors:
Journal: JAMA Date: 1993-06-16 Impact factor: 56.272

3. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis.

Authors: O Ziouzenkova; L Asatryan; M Akmal; C Tetta; M L Wratten; G Loseto-Wich; G Jürgens; J Heinecke; A Sevanian
Journal: J Biol Chem Date: 1999-07-02 Impact factor: 5.157

4. Human mesangial cells express inducible macrophage scavenger receptor.

Authors: X Z Ruan; Z Varghese; S H Powis; J F Moorhead
Journal: Kidney Int Date: 1999-08 Impact factor: 10.612

5. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors: William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245

6. Oxidation of low-density lipoproteins by rat mesangial cells and the interaction of oxidized low-density lipoproteins with rat mesangial cells in vitro.

Authors: R L Fernando; Z Varghese; J F Moorhead
Journal: Nephrol Dial Transplant Date: 1993 Impact factor: 5.992

7. Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis.

Authors: T Shoji; Y Nishizawa; H Nishitani; M Yamakawa; H Morii
Journal: Metabolism Date: 1991-10 Impact factor: 8.694

8. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.

Authors: Hallvard Holdaas; Bengt Fellström; Alan G Jardine; Ingar Holme; Gudrun Nyberg; Per Fauchald; Carola Grönhagen-Riska; Søren Madsen; Hans-Hellmut Neumayer; Edward Cole; Bart Maes; Patrice Ambühl; Anders G Olsson; Anders Hartmann; Dag O Solbu; Terje R Pedersen
Journal: Lancet Date: 2003-06-14 Impact factor: 79.321

9. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.

Authors: J Craig Longenecker; Josef Coresh; Neil R Powe; Andrew S Levey; Nancy E Fink; Alice Martin; Michael J Klag
Journal: J Am Soc Nephrol Date: 2002-07 Impact factor: 10.121

10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245

9 in total

1. Effectiveness of a diet with low advanced glycation end products, in improving glycoxidation and lipid peroxidation: a long-term investigation in patients with chronic renal failure.

Authors: N C Chilelli; D Cremasco; C Cosma; E Ragazzi; F Francini Pesenti; L Bonfante; A Lapolla
Journal: Endocrine Date: 2015-11-20 Impact factor: 3.633

Review 2. The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.

Authors: Maryam Jabarpour; Nadereh Rashtchizadeh; Hassan Argani; Amir Ghorbanihaghjo; Masoumeh Ranjbarzadhag; Davoud Sanajou; Fatemeh Panah; Amirhesam Alirezaei
Journal: Int Urol Nephrol Date: 2019-10-22 Impact factor: 2.370

3. Oxidized Low-Density Lipoprotein Predicts the Development of Renal Dysfunction in Atrial Fibrillation.

Authors: Marija Polovina; Ivana Petrović; Voin Brković; Milika Ašanin; Jelena Marinković; Miodrag Ostojić
Journal: Cardiorenal Med Date: 2016-09-16 Impact factor: 2.041

Review 4. Effects of dyslipidaemia on monocyte production and function in cardiovascular disease.

Authors: Mohammed Shamim Rahman; Andrew J Murphy; Kevin J Woollard
Journal: Nat Rev Cardiol Date: 2017-03-16 Impact factor: 32.419

5. Metabolic Syndrome and the Iodine-Dose/Creatinine Clearance Ratio as Determinants of Contrast-Induced Acute Kidney Injury.

Authors: Ali Amiri; Reza Ghanavati; Hassan Riahi Beni; Seyyed Hashem Sezavar; Mehrdad Sheykhvatan; Mahsa Arab
Journal: Cardiorenal Med Date: 2018-06-15 Impact factor: 2.041